Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1969 1
1981 1
1982 1
1983 2
1984 3
1985 3
1986 2
1987 4
1988 3
1989 7
1990 4
1991 3
1992 4
1993 3
1994 2
1995 4
1996 2
1997 2
1998 3
1999 3
2000 5
2001 2
2002 1
2003 2
2004 3
2005 2
2006 2
2007 1
2008 6
2009 3
2010 3
2011 3
2012 4
2013 2
2014 2
2015 5
2016 3
2017 7
2018 5
2019 6
2020 6
2021 9
2022 9
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence.
Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, Farag F, Groen J, Karavitakis M, Lapitan MC, Manso M, Arteaga SM, Riogh ANA, O'Connor E, Omar MI, Peyronnet B, Phé V, Sakalis VI, Sihra N, Tzelves L, van Poelgeest-Pomfret ML, van den Bos TWL, van der Vaart H, Harding CK. Nambiar AK, et al. Among authors: van den bos twl. Eur Urol. 2022 Jul;82(1):49-59. doi: 10.1016/j.eururo.2022.01.045. Epub 2022 Feb 23. Eur Urol. 2022. PMID: 35216856 Review.
What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
Farag F, Sakalis VI, Arteaga SM, Sihra N, Karavitakis M, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, Groen J, Peyronnet B, Phé V, van Poelgeest-Pomfret ML, van den Bos TWL, van der Vaart H, Harding CK, Carmela Lapitan M, Imran Omar M, Nambiar AK. Farag F, et al. Among authors: van den bos twl. Eur Urol. 2023 Sep;84(3):302-312. doi: 10.1016/j.eururo.2023.05.014. Epub 2023 Jun 17. Eur Urol. 2023. PMID: 37331921 Review.
European Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 2: Underactive Bladder, Bladder Outlet Obstruction, and Nocturia.
Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, Farag F, Groen J, Karavitakis M, Lapitan MC, Manso M, Arteaga SM, Nambiar AK, Riogh ANA, O'Connor E, Omar MI, Peyronnet B, Phé V, Sakalis VI, Sihra N, Tzelves L, van Poelgeest-Pomfret ML, van den Bos TWL, van der Vaart H, Harding CK. Arlandis S, et al. Among authors: van den bos twl. Eur Urol. 2022 Jul;82(1):60-70. doi: 10.1016/j.eururo.2022.01.044. Epub 2022 Feb 16. Eur Urol. 2022. PMID: 35181193 Review.
Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia.
Rutten MGS, Lei Y, Hoogerland JH, Bloks VW, Yang H, Bos T, Krishnamurthy KA, Bleeker A, Koster MH, Thomas RE, Wolters JC, van den Bos H, Mithieux G, Rajas F, Mardinoglu A, Spierings DCJ, de Bruin A, van de Sluis B, Oosterveer MH. Rutten MGS, et al. Among authors: bos t. Cancer Metab. 2023 Apr 21;11(1):5. doi: 10.1186/s40170-023-00305-3. Cancer Metab. 2023. PMID: 37085901 Free PMC article.
jun: oncogene and transcription factor.
Vogt PK, Bos TJ. Vogt PK, et al. Among authors: bos tj. Adv Cancer Res. 1990;55:1-35. doi: 10.1016/s0065-230x(08)60466-2. Adv Cancer Res. 1990. PMID: 2166997 Review. No abstract available.
Oncogenes and cell growth.
Bos TJ. Bos TJ. Adv Exp Med Biol. 1992;321:45-9; discussion 51. doi: 10.1007/978-1-4615-3448-8_6. Adv Exp Med Biol. 1992. PMID: 1333167 Review.
Fos-associated protein p39 is the product of the jun proto-oncogene.
Rauscher FJ 3rd, Cohen DR, Curran T, Bos TJ, Vogt PK, Bohmann D, Tjian R, Franza BR Jr. Rauscher FJ 3rd, et al. Among authors: bos tj. Science. 1988 May 20;240(4855):1010-6. doi: 10.1126/science.3130660. Science. 1988. PMID: 3130660 Review.
The oncogene jun and nuclear signalling.
Vogt PK, Bos TJ. Vogt PK, et al. Among authors: bos tj. Trends Biochem Sci. 1989 May;14(5):172-5. doi: 10.1016/0968-0004(89)90268-5. Trends Biochem Sci. 1989. PMID: 2505415 Review.
148 results